PTSD News

A biopharma company has received approval from the European Medicines Agency to commence a phase 1 clinical trial of its selective endocannabinoid reuptake inhibitor, which aims to restore healthy brain physiology.

The number of vacation days taken and time spent performing patient-related work while on vacation were associated with physician burnout, according to study results published in JAMA Network Open.

Patients with pulmonary fibrosis who used a smartphone app that offers cognitive behavioral therapy showed improvements in anxiety levels and quality of life, according to a press release.

Jazz Pharmaceuticals’ experimental PTSD treatment failed to meet the primary endpoint in a phase 2 trial, the company announced in a press release.

Focusing on mental health is one of the most popular New Year’s resolutions U.S. adults are making for 2024, according to a press release from the American Psychiatric Association.

A public benefit corporation that develops psychedelic therapies has submitted a new drug application to the FDA this week to use MDMA combined with psychotherapy to treat PTSD, according to a press release.

A new licensing agreement between Silo Pharma and Medspray Pharma BV allows SPC-15, Silo’s therapeutic for PTSD, anxiety and more, to be delivered via Medspray’s soft mist nasal spray technology, according to a Silo press release.

ORLANDO — Caregivers of patients in the U.K. with Dravet syndrome would benefit from better communication, access to health care and increased psychosocial interventions, per a poster at the American Epilepsy Society annual meeting.

With potential FDA approvals on the horizon, the controversy surrounding psychedelics in clinical practice may soon reach a tipping point, according to experts.

The FDA has issued a warning against the purchase or use of products that contain tianeptine, which has been illegally sold with claims to improve brain function and treat anxiety, depression, pain, opioid use disorder and other conditions.